Catalyst Oncology

Cancer and Oncology News

Catalyst Oncology header image 2

Acne Skin Care - Merck KGaA: Survival In 1st-Line Non-Small Cell Lung Cancer (NSCLC) Significantly Prolonged By Erbitux(R) (Medical News Today)

October 6th, 2008 · No Comments

Acne Skin Care - Merck KGaA: Survival In 1st-Line Non-Small Cell Lung Cancer (NSCLC) Significantly Prolonged By Erbitux(R) (Medical News Today) Posted on October 6, 2008 Filed Under acne skin care | Comments Off Merck KGaA: Survival In 1st-Line Non-Small Cell Lung Cancer (NSCLC) Significantly Prolonged By Erbitux(R) (Medical News Today) Data presented today at the 1st International Thoracic Oncology Congress Dresden (ITOCD) demonstrate that the addition of Erbitux® (cetuximab) to standard pla

See original here: 
Acne Skin Care - Merck KGaA: Survival In 1st-Line Non-Small Cell Lung Cancer (NSCLC) Significantly Prolonged By Erbitux(R) (Medical News Today)

Tags: oncology

0 responses so far ↓

  • There are no comments yet...Kick things off by filling out the form below.

You must log in to post a comment.